Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women.
Latha KadalayilSofia KhanHeli NevanlinnaPeter A FaschingFergus J CouchJohn L HopperJianjun LiuTom MaishmanLorraine DurcanSue GertyCarl BlomqvistBrigitte RackWolfgang JanniAndrew CollinsDiana EcclesWilliam TapperPublished in: Nature communications (2017)
To identify genetic variants associated with breast cancer prognosis we conduct a meta-analysis of overall survival (OS) and disease-free survival (DFS) in 6042 patients from four cohorts. In young women, breast cancer is characterized by a higher incidence of adverse pathological features, unique gene expression profiles and worse survival, which may relate to germline variation. To explore this hypothesis, we also perform survival analysis in 2315 patients aged ≤ 40 years at diagnosis. Here, we identify two SNPs associated with early-onset DFS, rs715212 (P meta = 3.54 × 10-5) and rs10963755 (P meta = 3.91 × 10-4) in ADAMTSL1. The effect of these SNPs is independent of classical prognostic factors and there is no heterogeneity between cohorts. Most importantly, the association with rs715212 is noteworthy (FPRP <0.2) and approaches genome-wide significance in multivariable analysis (P multivariable = 5.37 × 10-8). Expression quantitative trait analysis provides tentative evidence that rs715212 may influence AREG expression (P eQTL = 0.035), although further functional studies are needed to confirm this association and determine a mechanism.
Keyphrases
- prognostic factors
- genome wide
- free survival
- early onset
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- poor prognosis
- peritoneal dialysis
- dna methylation
- emergency department
- gene expression
- late onset
- mass spectrometry
- patient reported outcomes
- young adults
- oxidative stress
- adverse drug
- childhood cancer